41235-88-5

Upstream product

• 99-05-8 meta-aminobenzoic acid 
• 123-51-3 i-Amyl alcohol 
• 334932-13-7 3-[(tert-butoxycarbonyl)amino]cyclo-hexanecarboxylic acid 
• 81131-37-5 (1R,3S)-3-phthalimidocyclohexanecarboxylic acid 
• 16205-98-4 3-oxo-cyclohexanecarboxylic acid 
• 15111-56-5 ethyl-3-cyclohexene-1-carboxylate 
• 586-38-9 3-Methoxybenzoic acid 
• 81131-38-6 (1S,3R)-3-phthalimidocyclohexanecarboxylic acid 
• 4720-83-6 6-oxabicyclo[3.2.1]oct-3-en-7-one 
• 116724-13-1 trans rac-cyclohexyl 1,3-dicarboxylic acid 
• 81201-62-9 (d,l)-cis-3-phthalimidocyclohex-4-ene-1-carboxylic acid 
• 81202-30-4 (1S,5S)-5-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-cyclohex-3-enecarboxylic acid 
• 81086-73-9 ethyl cis-5-phthalimidocyclohex-3-ene-1-carboxylate 
• 81086-72-8 5-Bromo-cyclohex-3-enecarboxylic acid ethyl ester 

Downstream Products

• 53084-60-9 ethyl 3-aminocyclohexanecarboxylate 
• 478832-00-7 3-[(dibenzylamino)methyl]cyclohexanamine 
• 478831-94-6 tert-butyl 3-[(dibenzylamino)carbonyl]cyclohexanecarbamate 
• 478831-97-9 3-amino-N,N-dibenzylcyclohexanecarboxamide monohydrochloride 

Relevant academic research and scientific papers

Development of an Enantioselective Novozym 435 Mediated Acetylation for the Preparation of (1S,3R)-3-Acetamidocyclohexane-1-carboxylic Acid

Starting from a cheap and readily available starting material, a short and enantioselective route to (1S,3R)-3-acetamidocyclohexane-1-carboxylic acid was developed. The key steps were a rhodium catalyzed hydrogenation of 3-aminobenzoic acid and an enantioselective Novozym 435 mediated acetylation of racemic isopropyl 3-aminocyclohexanecarboxylate.

Directed, regiocontrolled hydroamination of unactivated alkenes via protodepalladation

A directed, regiocontrolled hydroamination of unactivated terminal and internal alkenes is reported. The reaction is catalyzed by palladium(II) acetate and is compatible with a variety of nitrogen nucleophiles. A removable bidentate directing group is used to control the regiochemistry, prevent β-hydride elimination, and stabilize the nucleopalladated intermediate, facilitating a protodepalladation event. This method affords highly functionalized amino acids in good yields with high regioselectivity.

Inhibitors of protein kinases

Compounds of general Formula (I): wherein R1, R2, R3, Ra, A, B and x are as defined herein are inhibitors of protein kinases in particular members of the cyclin-dependent kinase family and/or the glycogen synthase kinase 3 family and are useful in preventing and/or treating any type of pain, inflammatory disorders, cancer, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases, metabolic disorders, renal diseases, neurologic and neuropsychiatric diseases and neurodegenerative diseases.

An improved synthesis of (1R,3S)-3-[(tert-butoxycarbonyl)amino] cyclohexanecarboxylic acid

An improved synthesis of (1R,3S)-3-[(tert-butoxycarbonyl)amino] cyclohexanecarboxylic acid from 3-aminobenzoic acid is described utilising milder and more selective conditions. Both a classical salt resolution and an enzymatic approach have been shown to give the desired compound in high selectivity.

Self-assembled peptide tubelets with 7 A pores

Here we report the preparation and structural characteristics of self-assembling peptide tubelets composed of 32-membered rings formed of alternating cx-amino acids and cis-3-aminocyclohexanecarboxylic acids. The tubelets possess a partial hydrophobic cor

New cyclic peptide assemblies with hydrophobic cavities: The structural and thermodynamic basis of a new class of peptide nanotubes

A new class of self-assembling peptides based on cyclic peptides made of alternating 3-aminocyclohexanecarboxylic acid (γ-Acc) and α-amino acids is described. The studied cylindrical assemblies are models for a new class of self-assembling peptide nanotub

Substituted pyrroles suitable for continuous infusion

Disclosed are novel substituted pyrroles having the formula These compounds and their pharmaceutically acceptable salts are suitable for administration to patients as continuous infusion solution and are useful in the treatment and/or control of cell prol

2-aminopyridine derivatives and combinatorial libraries thereof

The present invention relates to novel 2-aminopyridine derivative compounds of the following formula: wherein R1to R5have the meanings provided herein. The invention further relates to combinatorial libraries containing two or more such compounds, as well as methods of preparing 2-aminopyridine derivative compounds.

Diaminopropionic acid derivatives

A compound of formula 1a which is useful for treating reperfusion injury, and salts, prodrugs, and related compounds.

Opioid deltorphin C analogues containing cis- or trans-2- or 3- or 4- aminocyclohexanecarboxylic acid residues

The solid phase synthesis, based on the Fmoc chemical protocol, was used to prepare ten deltorphin C (Del-C; H-Tyr-D-Ala-Phe-Asp-Val-Val-Gly-NH2) analogues containing cis- and trans- 2 or 3- or 4- aminocyclohexanecarboxylic acid (ACCA) residues at position 2, ACCA-peptides showed high resistance to degradation by plasma or brain enzymes, negligible affinity for the κ- binding site and modest δ- and/or μ-receptor affinities. Both [cis-3- ACCA2]Del-C analogues and one trans isomer are the only deltorphin analogues of this series exhibiting an appreciable δ-affinity and selectivity. These data suggest that the presence of a conformationally constrained ACCA residue in position 2 of the 'message' sequence of deltorphin C is slightly tolerated.